Cover Image
市場調查報告書

連續式血糖監測系統的歐洲市場:市場機會與預測 (2014∼2021年)

Europe Continuous Glucose Monitoring Systems Market - Opportunities and Forecasts, 2014 - 2021

出版商 Allied Market Research 商品編碼 354614
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
連續式血糖監測系統的歐洲市場:市場機會與預測 (2014∼2021年) Europe Continuous Glucose Monitoring Systems Market - Opportunities and Forecasts, 2014 - 2021
出版日期: 2016年02月01日 內容資訊: 英文 90 Pages
簡介

歐洲的連續式血糖監測系統市場,預測到2021年前將以年複合成長率38.0%擴大,達到3億5,170萬美元。由於微創,即時血糖監測系統等技術的進步等因素推動,預測該市場將更進一步大幅成長。

本報告提供歐洲的連續式血糖監測系統市場現狀與到2021年前的成長預測,提供您各國,各零件趨勢,加上市場趨勢與課題,並彙整主要企業的簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 概要

第4章 英國的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第5章 德國的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第6章 法國的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第7章 挪威的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第8章 瑞典的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第9章 丹麥的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第10章 芬蘭的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第11章 其他各國的連續式血糖監測系統市場

  • 市場趨勢
  • 成長因素和機會
  • 市場規模與預測
  • 償付方案

第12章 企業簡介

  • Medtronic Inc.
  • Dexcom Inc.
  • Abbott Diabetic Care(Abbott Laboratories)
  • Senseonics, Incorporated
  • Animas Corporation
  • Insulet Corporation
  • Echo Therapeutics
  • Glysens Inc.

圖表

目錄

Title: Europe Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & receivers, Integrated insulin pumps) - Opportunity Analysis and Industry Forecast, 2014 - 2021.

Continuous glucose monitoring system (CGMS) is a device that provides with the real-time glucose monitoring in diabetes patients. This technology helps diabetes patients to track their glucose levels round-the-clock. CGMS devices monitor glucose levels at an interval of every 5 minutes. CGMS devices are used along with blood glucose meters to provide supplementary information to facilitate better glucose monitoring and treatment. This technology can be used in diabetes type 1 as well as diabetes type 2 patients. Continuous glucose monitoring assist in stabilizing elevated A1C levels, thereby, reducing the risk of developing long-term diabetic complications. The adoption of CGMS technology is expected to increase, owing to its application in artificial/bionic pancreas.

The Europe CGMS market is estimated to garner $351.7 million by 2021, registering a CAGR of 38.0% during the forecast period. This market is expected to witness significant growth from 2015 to 2021, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increasing incidence of diabetes cases in Europe, increasing per capita healthcare expenditure, and growing purchasing power on account of high disposable income of individuals have fueled the market growth. Furthermore, ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring has supplemented the market growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and limited awareness about CGMS among patients are the major factors hampering the growth of the market.

The report segments the Europe CGMS market on the basis of country and components. Based on country, the market is segmented into the U.K., France, Germany, Norway, Sweden, Denmark, Finland and Other Europe. Presently, the Germany leads the Europe CGMS market, owing to its large diabetes patient pool and high healthcare expenditure. The components of the CGMS comprise sensors, transmitters & receivers, and integrated insulin pumps. The sensors segment dominates the market, as the sensor loses its sensitivity after using if for about 5 to 7 days, which requires frequent requirement.

Europe CGMS market has presence of numerous manufacturers that are adopting partnership and collaboration as their strategy to commercialize CGMS. For instance, Senseonics and Rubin Medical have adopted the collaboration strategy to commercialize their CGMS products in Denmark and Sweden. The companies profiled in the report include Medtronic Inc., Dexcom, Inc., Abbott Diabetic care, Senseonics Incorporated, Insulet Corporation, Echo therapeutics, Glysens Inc. and Animas Corporation,

KEY BENEFITS FOR STAKEHOLDERS:

  • This report provides an in-depth analysis of the current and emerging market trends and dynamics in the Europe CGMS market.
  • The European CGMS market is analyzed based on countries such as the U.K., France, Germany, Norway, Sweden, Denmark, Finland, and Other Europe.
  • An in-depth analysis of key strategies adopted by key manufacturers helps in understanding competitive scenario.
  • This report provides an exhaustive analysis of the factors that drive and restrict the growth of the Europe CGMS market.
  • The reimbursement scenario of CGMS devices has been provided in this report.

EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET KEY SEGMENTS:

BY COUNTRY

  • U.K.
  • France
  • Germany
  • Norway
  • Sweden
  • Denmark
  • Finland
  • Other Europe

BY COMPONENTS

  • Sensors
  • Transmitters & receivers
  • Integrated insulin pumps

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Market definition and scope
  • 1.2. Research methodology
    • 1.2.1. Secondary research
    • 1.2.2. Primary Research
    • 1.2.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021($THOUSANDS)

  • 3.1. Overview
    • 3.1.1. Market size and forecast

CHAPTER 4: U.K. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021($THOUSANDS)

  • 4.1. Key market trends
  • 4.2. Key growth factors and opportunities
  • 4.3. Market size and forecast
  • 4.4. Reimbursement scenario

CHAPTER 5: GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021($THOUSANDS)

  • 5.1. Key market trends
  • 5.2. Key growth factors and opportunities
  • 5.3. Market size and forecast
  • 5.4. Reimbursement scenario

CHAPTER 6: FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021($THOUSANDS)

  • 6.1. Key market trends
  • 6.2. Key growth factors and opportunities
  • 6.3. Market size and forecast
  • 6.4. Reimbursement scenario

CHAPTER 7: NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021($THOUSANDS)

  • 7.1. Key market trends
  • 7.2. Key growth factors and opportunities
  • 7.3. Market size and forecast
  • 7.4. Reimbursement scenario

CHAPTER 8: SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021,($THOUSANDS)

  • 8.1. Key market trends
  • 8.2. Key growth factors and opportunities
  • 8.3. Market size and forecast
  • 8.4. Reimbursement scenario

CHAPTER 9: DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021,($THOUSANDS)

  • 9.1. Key market trends
  • 9.2. Key growth factors and opportunities
  • 9.3. Market size and forecast
  • 9.4. Reimbursement scenario

CHAPTER 10: FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021,($THOUSANDS)

  • 10.1. Key market trends
  • 10.2. Key growth factors and opportunities
  • 10.3. Market size and forecast
  • 10.4. Reimbursement scenario

CHAPTER 11: OTHER EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2021,($THOUSANDS)

  • 11.1. Key market trends
  • 11.2. Key growth factors and opportunities
  • 11.3. Market Size and Forecast
  • 11.4. Reimbursement Scenario
    • 11.4.1. Israel
    • 11.4.2. The Netherlands
    • 11.4.3. Slovenia
    • 11.4.4. Spain
    • 11.4.5. Switzerland

CHAPTER 12: COMPANY PROFILES

  • 12.1. Medtronic Inc.
    • 12.1.1. Company overview
    • 12.1.2. Company snapshot
    • 12.1.3. Business performance
    • 12.1.4. Strategic moves and developments
      • 12.1.4.1. Principal strategies: product launch
      • 12.1.4.2. Secondary strategies: approval
      • 12.1.4.3. Other strategies: strategic alliance and collaboration
    • 12.1.5. SWOT analysis of Medtronic Inc.
  • 12.2. Dexcom Inc.
    • 12.2.1. Company overview
    • 12.2.2. Company snapshot
    • 12.2.3. Business performance
    • 12.2.4. Strategic moves and developments
      • 12.2.4.1. Principal strategies: agreement/partnership
      • 12.2.4.2. Secondary strategies: approval
      • 12.2.4.3. Other strategies: acquisition
    • 12.2.5. SWOT analysis of Dexcom
  • 12.3. Abbott Diabetic Care(Abbott Laboratories)
    • 12.3.1. Company overview
    • 12.3.2. Company snapshot
    • 12.3.3. Business performance
    • 12.3.4. Strategic moves and developments
    • 12.3.5. SWOT analysis of Abbott diabetic care
  • 12.4. Senseonics, Incorporated
    • 12.4.1. Company overview
    • 12.4.2. Company snapshot
    • 12.4.3. Strategic moves and development
    • 12.4.4. SWOT analysis of Senseonics
  • 12.5. Animas Corporation
    • 12.5.1. Company overview
    • 12.5.2. Company snapshot
    • 12.5.3. Strategic moves and developments
    • 12.5.4. SWOT analysis of Animas Corporation
  • 12.6. Insulet Corporation
    • 12.6.1. Company overview
    • 12.6.2. Company snapshot
    • 12.6.3. Strategic moves and developments
    • 12.6.4. SWOT analysis of INSULET Corporation
  • 12.7. Echo Therapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Company snapshot
    • 12.7.3. Strategic moves and development
    • 12.7.4. SWOT analysis of Echo Therapeutics
  • 12.8. Glysens Inc.
    • 12.8.1. Company overview
    • 12.8.2. Company snapshot
    • 12.8.3. Strategic moves and developments
    • 12.8.4. SWOT analysis of Glysens Inc.

List of Tables

  • TABLE 1: EUROPE CGMS MARKET BY COUNTRY, 2014-2021, ($THOUSANDS)
  • TABLE 2: U.K. CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 3: GERMANY CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 4: FRANCE CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 5: NORWAY CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 6: SWEDEN CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 7: DENMARK CGMS MARKET BY COMPONENTS, 2014-2021 ($THOUSANDS)
  • TABLE 8: FINLAND CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 9: OTHER EUROPE CGMS MARKET BY COMPONENTS, 2014-2021, ($THOUSANDS)
  • TABLE 10: MEDTRONIC BUSINESS SNAPSHOT
  • TABLE 11: DEXCOM INC. BUSINESS SNAPSHOT
  • TABLE 12: ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
  • TABLE 13: SENSEONICS SNAPSHOT
  • TABLE 14: ANIMAS CORPORATION BUSINESS SNAPSHOT
  • TABLE 15: INSULET CORPORATION BUSINESS SNAPSHOT
  • TABLE 16: GLYSENS INC. BUSINESS SNAPSHOT

List of Figures

  • FIG. 1: MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
  • FIG. 2: MEDTRONIC REVENUE BY GEOGRAPHY (2014)
  • FIG. 3: SWOT ANALYSIS OF MEDTRONIC
  • FIG. 4: SWOT ANALYSIS OF DEXCOM INC.
  • FIG. 5: REVENUE BY BUSINESS SEGMENT (2014)
  • FIG. 6: SWOT ANALYSIS OF ABBOTT DIABETIC CARE
  • FIG. 7: SWOT ANALYSIS OF SENSEONICS
  • FIG. 8: SWOT ANALYSIS OF ANIMAS CORPORATION
  • FIG. 9: SWOT ANALYSIS OF INSULET CORPORATION
  • FIG. 10: SWOT ANALYSIS OF ECHO THERAPEUTICS
  • FIG. 11: SWOT ANALASIS OF GLYSEN INCORPORATED
Back to Top